L&C BIO, a South Korean regenerative medicine company specializing in human tissue repair, has been officially included in the KRX300 index following the Korea Exchange’s regular rebalancing. The move signals growing institutional confidence in the company’s ECM-based platform, which spans surgical and aesthetic products, and is expected to attract passive fund inflows and improve liquidity for overseas buyers and distributors tracking the Korean aesthetic device and injectable market.
Index inclusion and market signal
The KRX300 is a flagship composite index covering 300 stocks from both the KOSPI and KOSDAQ markets, selected based on market capitalization, liquidity, financial health, and market representation. It is widely used by institutional investors and pension funds as a benchmark. L&C BIO’s inclusion reflects formal recognition of its business competitiveness, growth potential, and market standing in the regenerative aesthetics sector.
ECM platform and aesthetic product portfolio
L&C BIO is an ECM-based platform company offering a range of products from surgical solutions—such as Megaderm, Meganerve, and Megakaty—to aesthetic lines including the skin booster ‘Lituo’. The company is positioned at the forefront of a paradigm shift in skin regeneration and beauty, moving from traditional filler-based treatments toward fundamental ECM-based tissue regeneration.
Global expansion and sourcing context
The company is accelerating its global business expansion into Southeast Asia and North America, leveraging its ECM technology and product competitiveness. For overseas importers and distributors, L&C BIO’s index inclusion and growing product pipeline signal a reliable partner in the regenerative aesthetics supply chain, particularly for skin boosters and tissue repair solutions.
What buyers should watch
Distributors and clinic buyers should monitor L&C BIO’s expanding ECM-based aesthetic portfolio, especially the ‘Lituo’ skin booster, as the company targets broader international markets. The KRX300 inclusion may also enhance the company’s visibility among institutional investors, potentially leading to more stable pricing and supply for overseas partners.
Regulatory and channel signals
L&C BIO’s index entry underscores its compliance with rigorous financial and operational standards, which can serve as a proxy for product quality and regulatory reliability in the medical aesthetics space. This development may facilitate easier entry into regulated markets where supplier credibility is a key factor.
Source: Read the original report | Published: June 15, 2026